VRT106

DRUG5 trials

Sponsors

Guangzhou Virotech Pharmaceutical Co., Ltd., Guangdong Provincial People's Hospital

Conditions

Advanced Gastric CancerGlioblastomaHCCSolid TumorSolid Tumors

Phase 1

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

RecruitingNCT06368921

Guangzhou Virotech Pharmaceutical Co., Ltd.Solid Tumor

Start: 2024-06-19End: 2026-12-31Target: 30Updated: 2025-12-30

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

RecruitingNCT06826313

Guangzhou Virotech Pharmaceutical Co., Ltd.Solid Tumors

Start: 2025-03-19End: 2029-03-01Target: 12Updated: 2026-09-10

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

RecruitingNCT07093814

Guangzhou Virotech Pharmaceutical Co., Ltd.Glioblastoma

Start: 2025-09-02End: 2029-06-30Target: 42Updated: 2026-01-02

Phase 2

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Not yet recruitingNCT07486310

Guangdong Provincial People's HospitalAdvanced Gastric Cancer

Start: 2026-03-01End: 2029-06-01Target: 30Updated: 2026-03-20

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

RecruitingNCT07589244

Guangzhou Virotech Pharmaceutical Co., Ltd.HCC

Start: 2026-05-13End: 2029-06-30Target: 66Updated: 2026-05-15